Combined noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, et al. J Clin Invest 2022;132.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, et al. Combined noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. J Clin Invest 2022;132.
PMID: 35426377